ORIC Pharmaceuticals rakes in $53 mln Series B
South San Francisco-based cancer therapy company ORIC Pharmaceuticals has secured $53 million in Series B funding. The investors included The Column Group, Topspin Partners, OrbiMed Advisors, EcoR1 Capital, Foresite Capital and Kravis Investment Partners. In addition to the funding, Dr. Carl L. Gordon of OrbiMed and Dr. Leo A. Guthart of Topspin have been appointed to ORIC’s board.
2 December 2015•4 mins read
